News & media

Investor Presentation

News

Xlife Sciences Annual General Meeting approves all agenda items by a large majority and supports further expansion

Xlife Sciences Portfolio Company VERAXA Biotech Strengthens Financial Position with USD 27.5 Million Senior Secured Financing and USD 50 Million Equity Line

VERAXA Biotech Receives 99.57% Approval for Merger - Path to NASDAQ Listing Under «VRXA» Cleared

Xlife Sciences Portfolio Company VERAXA Biotech Successfully Completes Business Combination and Begins Trading on NASDAQ on June 11, 2026

New External Valuation Highlights Stability and Long-Term Value Potential of the Xlife Sciences AG Portfolio in the Valuation Report 2025

Xlife Sciences AG publishes 2025 Annual Report: Strategic positioning and preparation of key capital market transactions

Investor Presentation

View our latest investor presentation.

Robotic arm and surgeon with tablet over a holographic DNA helix and brain visualisation in a futuristic medical scene

Newsroom

Latest articles

Erster Börsengang einer Beteiligung dürfte Xlife kräftig Schub geben

Xlife Sciences Aktie: Segmentwechsel auf Generalversammlung 26. Juni

Xlife Sciences: Portfolio company VERAXA Biotech begins trading on NASDAQ

Continue learning

Download latest report

Valuation Report 2025

Laboratory microscope head and turret in soft focus beside a teal gradient background panel

Download latest report

Valuation Report 2025

Laboratory microscope head and turret in soft focus beside a teal gradient background panel